Xenothera

About:

Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments.

Website: http://www.xenothera.com/

Top Investors: Bpifrance, European Innovation Council, EIC Accelerator, EASME - EU Executive Agency for SMEs, Starquest Capital

Description:

Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.

Total Funding Amount:

26.5M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Nantes, Pays de la Loire, France

Founded Date:

2014-01-01

Contact Email:

contact(AT)xenothera.com

Founders:

Jean-Paul Soulillou, Odile Duvaux

Number of Employees:

1-10

Last Funding Date:

2021-06-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai